Clinical and Organizational Issues in the Management of Surviving Breast and Colorectal Cancer Patients: Attitudes and Feelings of Medical Oncologists

Gianmauro Numico1*, Carmine Pinto2, Stefania Gori3, Giovanni Ucci4, Massimo Di Maio5, Maurizio Cancian6, Francesco De Lorenzo7, Nicola Silvestris8

1 Medical Oncology Unit, Azienda USL della Valle d’Aosta, Aosta, Italy, 2 Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy, 3 Medical Oncology, Sacro Cuore Don Calabria Hospital, Verona, Italy, 4 Oncology Department, Azienda Ospedaliera di Lodi, Lodi, Italy, 5 Clinical Trial Unit, National Cancer Institute “G. Pascale” Foundation, Napoli, Italy, 6 Società Italiana di Medicina Generale (SIMG), Conegliano, Italy, 7 Federazione Associazioni di Volontariato in Oncologia (FAVO), Roma, Italy, 8 Medical Oncology Unit, National Cancer Research Centre “Giovanni Paolo II”, Bari, Italy

Abstract

Background: The fast growing demand and the shortage of resources are pushing toward more efficient models of survivorship care delivery. The Associazione Italiana di Oncologia Medica (AIOM) established an interdisciplinary working group with the purpose of promoting organizational improvements at the national level. A survey aimed at assessing attitudes and feelings of oncologists was considered preliminary to further initiatives.

Methods: A 25-item questionnaire, sent to the mailing list of the Society, explored the following issues on the practice of breast and colorectal cancer patients’ follow up: 1) organization; 2) clinical features; 3) feelings about the different meanings of follow-up.

Results: Ninety-one oncologists of 160 institutions (57%) answered to the questionnaire. Although follow up is considered a distinct oncological activity in 68%, a fully shared organization between specialists is not common and communications with Primary Care Physicians are not structured in the majority of the cases. Fifty-five and 30% of the oncologists follow breast and colorectal cancer patients indefinitely. In case of discharge a survivorship care plan is delivered in only 9%. The majority of respondents do not hold a role of follow up in mortality reduction.

Conclusions: Although survivorship care represents a significant part of the oncologists’ workload, an “oncology-centered” model is largely adopted and established care pathways are still incomplete. Survivorship care needs to be put at the center of an educational policy and of a widespread organizational effort, directed at improving appropriateness and quality.

Background

The number of people surviving to cancer is rapidly increasing and accounts approximately for the 6% of the adult population in developed countries [1,2]. Although some patient with a cancer history comes back to a completely healthy state [3] the majority is subject to disease and treatment-related conditions, is at risk of relapse and of other cancer and non-cancer diseases. The medical needs of cancer survivors are long-lasting: in most primaries clinical research has not been able to find clear time cutoffs after which the risk of relapse becomes comparable to that of the general population [4–6]. Moreover, some clinical conditions, such as anthracycline-related cardiotoxicity or secondary tumors are typically detected many years after the primary cancer [7,8]. Survivors are thus carriers of multiple medical needs and survivorship care is becoming a requested, multidimensional medical activity [9]. However, the increasing prevalence of cancer and the shortage of economical and human resources [10–13] is making critical the delivery of appropriate care.

An evolution of organizational models of care delivery, the sharing of medical skills and the promotion of definite and cost-effective care pathways are thus considered crucial issues [14]. Randomized trials have shown that efficient models of survivorship care can be introduced in clinical practice without impairing the quality of assistance and patients satisfaction: PCP-based follow up [15–17] nurse-based follow up [18] or simplified specialist schedules [19,20].

Citation: Numico G, Pinto C, Gori S, Ucci G, Di Maio M, et al. (2014) Clinical and Organizational Issues in the Management of Surviving Breast and Colorectal Cancer Patients: Attitudes and Feelings of Medical Oncologists. PLoS ONE 9(7): e101170. doi:10.1371/journal.pone.0101170

Editor: Antonio Moschetta, University of Bari & Consorzio Mario Negri Sud, Italy
Received April 27, 2014; Accepted June 3, 2014; Published July 1, 2014

Copyright: © 2014 Numico et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. We confirm that all data underlying the findings in the study are available upon request in the AIOM (Associazione Italiana di Oncologia Medica) repository. They are not made available in the manuscript because they were obtained from medical oncologists to whom a formal consensus to a free access to the survey was not asked for. For any need to have the data please contact the AIOM secretary through the web site (www.aiom.it).

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* Email: gnumico@ausl.vda.it
In the Italian context, from the usually adopted “oncology centered” model, a “sequential” model is gaining acceptance: after an arbitrarily defined period of specialist follow up, patients are discharged and sent to the PCP. While the sequential model is an easy way of discharging patients, it would imply a detailed transmission of clinical informations and the availability of efficient ways of re-enter in the specialist circuit in case of suspected relapse or complex conditions. A proposed alternative is the “shared cares” model [14] that promotes a continuous interaction between specialists and PCP throughout the whole clinical history with different roles of clinical actors in different times. This model requires high quality interactions, definite procedures and above all a well-defined communication infrastructure consisting in shared medical records.

Whatever the model, a new attitude to share competences and practices is required to the medical oncologist, together with an organizational effort aimed at maintaining quality and improving the efficiency of survivorship care. The main issues to be evaluated are: 1) the peculiar requirements of follow-up consultations in terms of know-how and organization, 2) the interaction with other specialists involved in survivorship care (surgeons and radiotherapists among all), 3) the appropriateness of medical procedures. 4) the relationship with PCP. All these aspects are influenced by deep and personal beliefs about the purposes of follow-up consultations.

We were interested in going into both the feelings and practical solutions adopted by Italian medical oncologists: an improvement in this field could hardly be a matter of the single center or the single oncologist. Rather, attitudes, ideas and obstacles are widespread at a national level as strictly reflect the overall quality of the national health care system. Having a real picture of how oncologists deal with survivorship care was considered a necessary preliminary step for further suggestion of possible organizational improvements.

**Methods**

The “Associazione Italiana di Oncologia Medica” (AIOM), in recent years established a working group with the aim of studying the issues related to the practice of survivorship care and of making proposals about possible organizational improvements. The working group is composed of medical and radiation oncologists, PCPs and representatives of patients advocacy associations. Due to the heterogeneity of follow-up practices among oncologists and the lack of standardized procedures, it was decided that the first objective of the group should have been a thorough knowledge of feelings and attitudes of medical oncologists about survivorship care. A 25-item questionnaire was sent three times to the mailing list of the Society, in a 2-months period. One oncologist per institution was asked to anonymously answer to the questions. After an introductory section dealing with institution characteristics, the following sections were presented: 1) organizational aspects of follow-up consultations; 2) clinical aspects involving breast and colorectal cancer follow-up; 3) feelings of medical oncologists about various meanings of follow-up.

According to the National regulations no Ethical Committee approval was deemed necessary, given the absence of data about patients. Instead, a privacy statement was provided to every responding oncologist.

The data entry was done by AIOM and descriptive statistics of the data were performed used Excel software (Office 2010). After the analysis, the results were discussed in the working group and further activity was planned accordingly.

**Results**

Ninety-one medical oncologists of the 160 Italian institutions answered to the questionnaire (response rate 57%). Characteristics of the answering oncologists and their institutions are shown in table 1. There was a prevalence of northern centers (58%) and of general hospitals (75%). Among respondents 41% were heads of department. The majority of the respondents take care of more than 100 and less than 100 new breast and colorectal cancer patients every year respectively.

**Organization of follow-up**

The complete list of questions and answers is shown in table 2. For 62 (68%) oncologists follow up represents a distinct medical activity, with dedicated times and waiting list, while for 29 (32%) follow up consultations are mixed with those of patients with active disease. The duration of the follow up consultation is 20 minutes or less in 64%. The estimated weekly time dedicated to follow up is between 8 and 32 hours in 69% of cases.

Some form of alternation of the visits of the various specialists that are involved in follow up is applied in 36% in breast cancer follow up and 13% in colorectal cancer follow up, while a fully shared organization is reported in 36% and 40% respectively. However, a shared medical record is used in only 19% and 11% of the respondents respectively.

Medical oncologists refer patients to their PCP for booking next consultations in 56% of the cases, while an autonomous request is filled in 34% (Table 3). The figures referring to laboratory and imaging are 54% and 38% respectively. In case of suspicious signs or symptoms occurring between programmed appointments, an accelerated referral to the oncological center is possible in 85%. The ordinary communication between the oncologist and the PCPs consists in the medical report released to the patient (87%) and only rarely in other instruments (dedicated phone line, booklets or dedicated informative material, 8%). Also, when the patient is discharged from the oncological follow up, a conclusive letter is sent to the PCP in 74% of the cases, while a full survivorship care plan or other informative material is delivered only in 9%. When is asked to the oncologists what should be the role of PCP in their opinion the answer is that it should be better exploited in the majority of the cases (89%) and only 4% answer that it is useless or irrelevant.

**Clinical aspects of follow up**

The majority of oncologists report to adopt institutional guidelines for follow up (74% breast, 77% colorectal cancer). 55% say to follow breast cancer patients indefinitely while 45% establish a time after which the patient is discharged to the PCP: for 38% the cutoff is 3 years and for 7% is 10 years after primary treatment. Colorectal cancer patients are followed indefinitely by 30% of the oncologists while in 70% a cutoff is established (at 2–3 years in 2%, at 5 years in 62% and at 10 years in 4%).

The general physical exam is considered useful and performed by 81% and 76% of the oncologists for breast and colorectal cancer patients respectively. Among the examinations requested independently from clinical findings, 47% of the oncologists claim to order imaging, 76% order tumor markers and 66% order biochemistry not recommended by any breast cancer follow up guideline (Figure 1). For colorectal cancer follow up, requested inappropriate tests are tumor markers other than CEA (requested by 50%) and biochemistry (requested by 69%) (Figure 2).
Perceived meaning of follow up

The final part of the survey assessed the meaning of follow up as perceived by oncologists (Figure 3). Only 6% and 14% of the oncologists feel that follow up has an important role in reducing mortality or anticipating the detection of recurrences in breast cancer. These figures grow to 31% and 47% for colorectal cancer. An important role for management of late toxicities is perceived by 26% for breast cancer and 17% for colorectal cancer. Management of comorbidities is perceived a major role in survivorship care by 24% for breast and 17% for colorectal cancer. The educational role is considered important in 36% and 32% while the psychological and supportive role for 44% and 37%.

Discussion

Follow up is an increasing part of oncologists working time. Although the estimated weekly time dedicated to this practice is

Table 1. Characteristics of responding oncologists and institutions.

| Characteristics                                      | N  | %  |
|------------------------------------------------------|----|----|
| **Geographic area**                                  |    |    |
| Northern                                             | 53 | 58%|
| Central                                              | 14 | 15%|
| Southern and major isles (Sardinia, Sicily)          | 20 | 22%|
| Not reported                                         | 4  | 4% |
| **Position of the oncologist**                       |    |    |
| Head of department                                   | 37 | 41%|
| Other role                                           | 54 | 59%|
| **Institution**                                      |    |    |
| General Hospital                                     | 68 | 75%|
| University Hospital                                  | 14 | 15%|
| Mixed                                                | 3  | 3% |
| Private                                              | 6  | 7% |
| **Number of beds of the institution**                |    |    |
| 0–300                                                | 37 | 41%|
| 300–600                                              | 34 | 37%|
| >600                                                 | 13 | 14%|
| Not reported                                         | 7  | 8% |
| **Number of oncologists in the department**          |    |    |
| 1–5                                                  | 26 | 29%|
| 6–10                                                 | 42 | 46%|
| >10                                                  | 21 | 23%|
| Not reported                                         | 2  | 2% |
| **Organization of the oncology department**          |    |    |
| Only Day Hospital/ambulatory service available        | 33 | 36%|
| Beds available                                       | 58 | 64%|
| **Number of new cancer patients seen yearly**        |    |    |
| 100–400                                              | 19 | 21%|
| 400–1000                                             | 39 | 43%|
| >1000                                                | 14 | 15%|
| Not reported                                         | 19 | 21%|
| **Number of new breast cancer patients seen yearly** |    |    |
| 20–100                                               | 32 | 35%|
| 100–200                                              | 25 | 27%|
| >200                                                 | 29 | 32%|
| Not reported                                         | 5  | 6% |
| **Number of new colorectal cancer patients seen yearly** |    |    |
| 20–100                                               | 49 | 54%|
| 100–200                                              | 21 | 23%|
| >200                                                 | 14 | 15%|
| Not reported                                         | 7  | 8% |
reported to be between 8 and 32 hours in almost 70% of the cases, in 32% the follow up consultation has not a specific organization and a dedicated time, separated from consultations of patients with active disease, leaving the recognition of related workload largely underestimated.

It is generally recognized that follow up consultations have distinct characteristics, that differ from other types of medical consultations: 1) they are a “low-efficiency” activity: many patients are to be seen in order to detect a single event; 2) they are quite simple, being clinical examination and few, usually well-defined laboratory or imaging studies routinely requested; 3) the supportive and educational role of the physician are crucial. Actually physical examination is ordinarily performed and the time employed for a single visit is usually brief (20 minutes or less in 64%). All these features would suggest that survivorship care be applied in a specific organizational context: while it seems to be the case for the majority of Italian oncologists, AIOM supports more effort in improving efficiency of this practice, being the shortage of oncological workforce an impending issue [11–13].

Another issue highlighted by the survey is the quality of oncological surveillance and the appropriateness of diagnostic tests in asymptomatic patients. As already reported in other contexts, “cancer patients commonly undergo much more intensive surveillance than is commonly recommended by guidelines” [21–23]. Although discouraged by available guidelines, more than half of the surveyed oncologists ask for tumor markers in breast cancer, markers other than CEA and blood chemistry in colorectal cancer (figure 1). This finding may be the result of insufficient knowledge and unreliable data on cancer surveillance in breast and colorectal cancer: recommendations are based on old studies and do not consider the different risk of disease subgroups [24–25]. However, given the unproven benefits of a more intensive follow up, a strict and uniform adherence to guidelines should be pursued by our Society.

As expected, the model of care delivery is not homogeneous among Italian oncologists. More than half of them claim to take care indefinitely of breast cancer patients; the percentage is lower for colorectal cancer (30%) but stands for a still rooted “oncology centered” model. Although the “sequential” model (specialist phase followed by PCP phase) is frequently adopted, the survey highlighted organizational flaws in the transition process. Before discharge, the main problems seem to be a scarce interaction among specialists (that often independently schedule consultations and examinations and do not use a common medical record) and undefined modalities of booking appointments (with the PCP often involved as an administrative prescriber of clinical or instrumental examinations decided elsewhere). All these issues possibly result in redundancy and inefficiency and are cause of patients’ discomfort and confusion. The transition from specialist to PCP care does not seem to be fully managed: a survivorship care plan is released in less than 10% of the cases and only the report of the last consultation is sent to the PCP in the majority of the cases.

Table 2. Questionnaire items: organizational features.

| Question | Answers | N   | %   |
|----------|---------|-----|-----|
| Do you have dedicated follow-up ambulatories? | Yes | 62 | 68% |
| | No | 29 | 32% |
| How much time do you spend for the follow-up visit? | Less than 20 min | 14 | 15% |
| | 20 min | 45 | 49% |
| | 30 min | 19 | 21% |
| | Variable | 9 | 10% |
| | Not stated | 4 | 4% |
| How many hours a week are spent for follow-up visits in your institution? | Less than 8 | 15 | 16% |
| | 8–16 | 34 | 37% |
| | 16–32 | 29 | 32% |
| | More than 32 | 13 | 14% |
| Is there an agreement between specialists for the rationalization of follow-up? Breast Cancer (1 not applicable) | Yes | 32 | 36% |
| | No formal agreement but some form of alternation of the visits | 32 | 36% |
| | No | 26 | 29% |
| Is there an agreement between specialists for the rationalization of follow-up? Colorectal Cancer (1 not applicable) | Yes | 36 | 40% |
| | No formal agreement but some form of alternation of the visits | 12 | 13% |
| | No | 42 | 47% |
| Is the medical record shared by all the specialists? Breast cancer (1 not applicable) | Yes | 17 | 19% |
| | No | 55 | 61% |
| | No but informations are available | 18 | 20% |
| Is the medical record shared by all the specialists? Colorectal cancer (1 not applicable) | Yes | 10 | 11% |
| | No | 59 | 66% |
| | No but informations are available | 21 | 23% |

doi:10.1371/journal.pone.0101170.t002

Follow Up Practices for Breast and Colorectal Cancer Patients
### Table 3. Questionnaire items: relationships with the Primary Care Physician (PCP).

| Question                                                                 | Answers                                      | N   | %   |
|--------------------------------------------------------------------------|----------------------------------------------|-----|-----|
| Who fills the request form of the follow up visit?                       | Oncologist                                   | 31  | 34% |
|                                                                          | PCP                                          | 51  | 56% |
|                                                                          | Both                                         | 9   | 10% |
| The reservation of the next visit*:                                      | Is provided by the oncologist                | 52  | 57% |
|                                                                          | Is made by the patient at the Hospital booking center | 47  | 52% |
|                                                                          | Is possible by phone or internet              | 35  | 38% |
| Laboratory and imaging examination are requested and booked by:          | Oncologist                                   | 35  | 38% |
|                                                                          | PCP                                          | 49  | 54% |
|                                                                          | Both                                         | 7   | 8%  |
| If the patient has a warning sign or symptom between the follow up visits*: | Can refer to the Oncologist through an urgent reservation | 77  | 85% |
|                                                                          | Refers to the PCP for the first level diagnostic work-up | 12  | 13% |
|                                                                          | Refers to the emergency department           | 9   | 10% |
|                                                                          | Waits for the next visit                     | 0   | 0   |
| What instruments are used to communicate with the PCP during follow up?  | Report of the consultation given to the patient (only) | 79  | 87% |
|                                                                          | Additional informative booklets dealing with survivorship care | 4   | 4%  |
|                                                                          | Additional dedicated telephone line          | 4   | 4%  |
|                                                                          | No communication is planned                  | 4   | 4%  |
| Is there a survivorship care plan to be delivered to the PCP at the end of the oncological follow up? | Only report of the discharge visit given to the patient | 67  | 74% |
|                                                                          | Informative booklets dealing with survivorship care | 8   | 9%  |
|                                                                          | No communication is planned                  | 16  | 17% |
| What do you think about the role of the PCP in follow up?                | Is essential                                 | 6   | 7%  |
|                                                                          | Should be better exploited                   | 81  | 89% |
|                                                                          | Is irrelevant                                | 1   | 1%  |
|                                                                          | It adds a useless step in survivorship care  | 3   | 3%  |

*More than one choice was possible, thus the sum being more than 91.
doi:10.1371/journal.pone.0101170.t003

### Table 4. Questionnaire items: clinical issues.

| Question                                                                 | Answers                                      | N   | %   |
|--------------------------------------------------------------------------|----------------------------------------------|-----|-----|
| Do you use internal/institutional guidelines? Breast cancer (1 not applicable) | Yes                                          | 67  | 74% |
|                                                                          | No                                           | 23  | 26% |
| Do you use internal/institutional guidelines? Colorectal cancer (1 not applicable) | Yes                                          | 69  | 77% |
|                                                                          | No                                           | 21  | 23% |
| For how much time you follow your patients? Breast cancer (2 not applicable) | 2–3 years                                    | 0   | 0   |
|                                                                          | 5 years                                      | 34  | 38% |
|                                                                          | 10 years                                     | 6   | 7%  |
|                                                                          | Indefinitely                                 | 50  | 55% |
| For how much time you follow your patients? Colorectal cancer (2 not applicable) | 2–3 years                                    | 2   | 2%  |
|                                                                          | 5 years                                      | 55  | 62% |
|                                                                          | 10 years                                     | 4   | 4%  |
|                                                                          | Indefinitely                                 | 27  | 30% |
| Do you usually perform a thorough physical examination? Breast cancer (1 not applicable) | Yes                                          | 81  | 90% |
|                                                                          | No                                           | 1   | 1%  |
|                                                                          | Only if clinically indicated                  | 8   | 9%  |
| Do you usually perform a thorough physical examination? Colorectal cancer (1 not applicable) | Yes                                          | 76  | 84% |
|                                                                          | No                                           | 3   | 3%  |
|                                                                          | Only if clinically indicated                  | 11  | 23% |

doi:10.1371/journal.pone.0101170.t004
Although a recent randomized trial did not demonstrate a clear impact on the quality of care \cite{26,27}, survivorship care plans have been strongly recommended by international institutions \cite{28,29,21–23} and are considered a key tool for a simple management of the informations’ flow. The transition of care should be planned in detail and bidirectional communications should be clear and informative. The 2005 Institute of Medicine report recommended the use of survivorship care plans as a tool to help patients and PCP providing appropriate care and prevent from discontinuing care when specialist follow up ends \cite{28}.

Actually the large majority of oncologists consider important the role of PCP or state that his/her function should be better exploited. This has not been the case in the recently reported American survey on breast cancer, in which more than two-thirds of oncologists do not think that PCP have the necessary skills to provide follow up care and 58% of the oncologists consequently favor an “oncology centered” model \cite{30}.

The perceived meaning of follow up as a survival-improving practice is another important issue: two-thirds and one-third of the surveyed oncologists do not consider relevant the impact on survival of follow up practices in breast and colorectal cancer respectively (figure 2). This finding is in line with the available informations: accumulating evidences suggest a limited role of breast cancer follow up \cite{31}, while patients with a history of colorectal cancer probably have some survival benefit \cite{32}. For all of the other items the role of surveillance is perceived more important, with the highest values achieved for the psychological and supportive role. A growing propensity of thinking at follow up as a practice that involves global care of the surviving patient is probably a message of the survey.

Inherent limitations of our data must be taken into account in interpreting the results. A selection bias is likely: the respondents are probably those already involved in the reflection and organizational effort about survivorship care and thus may represent the more sensible component of Italian medical oncology in this field. This could have resulted in an overestimation of the quality of oncological surveillance. Also, the limited number of respondents, although probably representative of the

Figure 1. Which exams do you ask independently from clinical findings with the purpose of early diagnosis of relapse? Breast Cancer.
doi:10.1371/journal.pone.0101170.g001

Figure 2. Which exams do you ask independently from clinical findings with the purpose of early diagnosis of relapse? Colorectal cancer.
doi:10.1371/journal.pone.0101170.g002
Figure 3. Do you agree that follow up has an important role in A: mortality reduction; B: reduction of the risk of relapse; C: management of late toxicities; D: education and life style change; E: management of comorbidities; F: psychological support. 1: breast cancer; 2: colorectal cancer. doi:10.1371/journal.pone.0101170.g003

Acknowledgments
We thank Eleonora Numico and Cecilia Bettinelli for the contribution to the data entry and the editorial assistance.

Authors’ information: GN is the coordinator of the working group on follow up for the Associazione Italiana di Oncologia Medica (AIOM); CP is the elected president of the Associazione Italiana di Oncologia Medica (AIOM); SG is the secretary of the Associazione Italiana di Oncologia Medica (AIOM).

Author Contributions
Conceived and designed the experiments: GN CP. Performed the experiments: GU MD MC FD. Analyzed the data: GN CP NS. Contributed to the writing of the manuscript: GN CP NS.

Follow up is an important and increasing practice for medical oncologists. While there are areas of huge inappropriateness that should be dealt with, the transition to a real survivorship care should be encouraged and promoted in order to cover the needs of global care of the patients with cancer history.

Conclusions

Follow up is an important and increasing practice for medical oncologists. While there are areas of huge inappropriateness that should be dealt with, the transition to a real survivorship care should be encouraged and promoted in order to cover the needs of global care of the patients with cancer history.

References

1. Jacobs LA, Palmer SC, Schwartz LA, De Michele A, Mao JJ, et al. (2009) Adult Cancer Survivorship: Evolution, Research, and Planning Care. CA Cancer J Clin Oncol 59: 391–410.
2. I numeri del cancro in Italia. Available: http://www.aiom.it. Accessed on March 9, 2014.
3. Harrison SE, Watson EK, Ward AM, Khan NF, Turner D, et al. (2011) Primary health and supportive care needs of long-term cancer survivors: a questionnaire survey. J Clin Oncol 29: 2091–2096.
4. Wheeler T, Stennng S, Negus S, Picken S, Metcalfe S (1999) Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis. Clin Oncol 1: 169–173.
5. Jatoi I, Anderson WF, Jrong JH, Redmond CK (2011) Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 29: 2301–2304.
6. Colzani E, Lägsgren A, Johansson ALV, Adolfsn J, Hellborg H, et al. (2011) Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 29: 4014–4021.
7. Azim HA, de Azambuja E, Coleozzo M, Bines J, Piccart MJ (2011) Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 22: 1939–1947.
8. Schaier C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96(17): 1311–1321.
9. Grunfeld E (2006) Looking beyond survival: How are we looking at survivorship? J Clin Oncol 24: 5166–5169.
10. Bunnel CA, Shulman LN (2010) Will we be able to take care of cancer patients in the future? Oncology 24: 1343–1348.
11. Eriksson C, Salberg E, Forte G, Brunnooge S, Goldstein M (2007) Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract 3(2): 79-86.
12. Debono D (2011) Coping with the oncology workforce shortage: transitioning oncology follow-up care to primary care providers. J Oncol Pract 6:201–205
13. Fasola G, Aprile G, Aita M (2011) A model to estimate human resource needs for the treatment of outpatients with cancer. J Oncol Pract 8: 15–17.
14. Oellinger KC, McCalbe MS (2006) Models for delivering survivorship care. J Clin Oncol 24: 5117–5124.
15. Grunfeld E, Mant D, Yuval P, Adeowi-Dalton R, Cole D, et al. (1996) Routine follow-up of breast cancer in primary care: randomised trial. British Med J 313(7058): 665–669.
16. Grunfeld E, Levine MN, Julian JA, Coyle D, Szechman B, Miskin D, et al. (2006) Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 24: 846–855.
17. Watchow DA, Weller DP, Esterman A, Pilots LS, McMorn K, Hammet Z, et al. (2006) General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer 94: 1116–1121.
18. Beaver K, Tyssor-Robinson D, Campbell M, Twomey M, Williamson S, Hindley A, et al. (2009) Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial. Br Med J 330: 1–9.
19. Guilford T, Opmou M, Wilson E, Hanham I, Epstein R (1997) Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. Br Med J 314: 171–177.
20. Turner RM, Bell KJL, Morton RL, Hayen A, Brecht Franken A, et al. (2011) Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 29: 4641–4646.
21. Earle CC (2008) Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol 24: 5112–5116.
22. Grunfeld G, Hodgson DC, Del Giudice ME, Moinedin R (2010) Population-based longitudinal study of follow-up care for breast cancer survivors. J Oncol Pract 6: 174–181.
23. Grunfeld E, Earle CC (2010) The Interface Between Primary and Oncology Specialty Care: Treatment Through Survivorship. J Natl Cancer Inst Monogr 40: 25–30.
24. The GIVIO Investigators (1994) Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 271(20):1587–92.
25. Rosselli Del Turco M, Palli D, Cariddi A, Giatto S, Pacini P, et al. (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 271(20): 1593–1597.
26. Grunfeld E, Julian JA, Pond G, Maunsell E, Coyle D, et al. (2011) Evaluating survivorship care plans: Results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol 29: 4735–4762.
27. Smith TJ, Snyder C (2011) Is it time for (survivorship care) plan B? J Clin Oncol 29: 4740-4742.
28. Institute of Medicine (2005) From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press.
29. Ganz PA, Hahn EE (2008) Implementing a survivorship care plan for patients with breast cancer. J Clin Oncol 26: 759-767.
30. Virgo KS, Lerro CC, Klabunde CN, Earle C, Ganz PA (2013) Barriers to breast and colorectal cancer survivorship care: perceptions of primary care physicians and medical oncologists in the United States. J Clin Oncol 31: 2322-2336.
31. Jacobs HJM, van Dijk JAE, de Kleijn EJMA, Kiemeny LAM, Verbeek ALM (2001) Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: A simulation study. Ann Oncol 12: 107–1113.
32. Desch CE, Benson AB III, Somerfield MR, Flynn PJ, Krause CK, et al. (2005) for the American Society of Clinical Oncology. Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 23: 4512-4519.